Clinical Trial Update: A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 randomized trial investigating Fel d 1 peptide immunotherapy for cat allergy hypersensitivity; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cat Allergy
• Cat Hypersensitivity

Drugs mentioned

• Fel d 1 peptide immunotherapy

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cat Allergy, Cat Hypersensitivity | Phase 2 | Status: COMPLETED